INFLUENCE OF PH ON THE CYTOTOXICITY OF CISPLATIN IN EMT6 MOUSE MAMMARY-TUMOR CELLS

被引:0
作者
LAURENCOT, CM [1 ]
KENNEDY, KA [1 ]
机构
[1] GEORGE WASHINGTON UNIV,DEPT PHARMACOL,WASHINGTON,DC 20037
关键词
CISPLATIN; TUMOR MICROENVIRONMENT; LOW PH; CISPLATIN RESISTANCE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pathophysiological factors exist within solid tumors that lead to a low pH environment. Therefore, pH-sensitive cancer chemotherapeutic agents may selectively target and kill tumor cells while sparing the normal tissue from toxicity. Using colony forming assays to assess cell survival, we found that EMT6 mouse mammary tumor cells were more sensitive to cisplatin cytotoxicity when cultured in pH 6.0 medium than in pH 7.2, 6.8, or 6.4 medium. The pH-dependent cytotoxicity of cisplatin resulted from an increase in cisplatin accumulation and an increase in the amount of DNA cross-links at pK 6.0 compared with pH 7.2. Because DNA is the cytotoxic target of cisplatin, intracellular pH (pHi) may be an important factor in determining the cytotoxicity of anticancer drugs at low extracellular pH (pHe). Therefore, manipulating the pHi of cells could be one method to enhance the effectiveness of the pH-sensitive chemotherapeutic agents. The pHi of EMT6 cells varied with pHe: at pHe 7.2, pHi was 7.54; at pHe 6.8, pHi was 7.29; at pHe 6.4, pHi was 7.02; and at pHe 6.0, pHi was 6.64. Using inhibitors to the ion transport mechanisms which regulate pHi, 5-N,N-hexamethylene amiloride (NHMA) and 4-acetamido-4'-isothiocyanostilbene-2.2' acid (SITS), the pHi and pHe of EMT6 cells were equilibrated. To evaluate the importance of pHi in determining drug toxicity, cell survival was determined for cells treated with cisplatin in the presence of NHMA and SITS. Cells cultured with NHMA and SITS were less sensitive to cisplatin. The cisplatin resistance obtained was independent of pH and could be attributed to the presence of SITS.
引用
收藏
页码:371 / 379
页数:9
相关论文
共 37 条
  • [31] Low-dose Cisplatin Induces Tumor Growth via Mobilization of Proangiogenic Bone Marrow-derived Cells in Mouse Models
    Cheng, Kai
    Tang, Fengru
    Liu, Xuanlin
    Wei, Junsong
    You, Huining
    Du, Qinglu
    Lin, Yanlan
    Feng, Weiyi
    [J]. ANTICANCER RESEARCH, 2023, 43 (12) : 5509 - 5522
  • [32] Elimination of mouse tumor cells from neonate spermatogonial cells utilizing cisplatin-entrapped folic acid-conjugated poly(lactic-co-glycolic acid) nanoparticles in vitro
    Shabani, Ronak
    Ashjari, Mohsen
    Ashtari, Khadijeh
    Izadyar, Fariborz
    Behnam, Babak
    Khoei, Samideh
    Asghari-Jafarabadi, Mohamad
    Koruji, Morteza
    [J]. INTERNATIONAL JOURNAL OF NANOMEDICINE, 2018, 13 : 2943 - 2954
  • [33] MiR-182-5p functions as a tumor suppressor to sensitize human ovarian cancer cells to cisplatin through direct targeting the cyclin dependent kinase 6 (CDK6)
    Duan, Li
    Yan, Ying
    Wang, Guan
    Xing, Yan-ling
    Sun, Jie
    Wang, Li-li
    [J]. JOURNAL OF BUON, 2020, 25 (05): : 2279 - 2286
  • [34] The combination therapy of HIF1α inhibitor LW6 and cisplatin plays an effective role on anti-tumor function in A549 cells
    Mai, L.
    Luo, M.
    Wu, J. J.
    Yang, J. H.
    Hong, L. Y.
    [J]. NEOPLASMA, 2019, 66 (05) : 776 - 784
  • [35] Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma
    Chang, Chun-Jung
    Yang, Yao-Hsu
    Chiu, Chiao-Juno
    Lu, Li-Chun
    Liao, Chien-Chia
    Liang, Cher-Wei
    Hsu, Chih-Hung
    Cheng, Ann-Lii
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (09) : 1878 - 1889
  • [36] The effect of free and encapsulated cisplatin into long-circulating and pH-sensitive liposomes on IEC-6 cells during wound healing in the presence of host-microbiota
    Araujo, Raquel Silva
    Cristina Oliveira, Monica
    Cardoso, Valbert Nascimento
    Keefe, Dorothy M. K.
    Stringer, Andrea M.
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2022, 74 (05) : 711 - 717
  • [37] Weakening Impact of Excessive Human Serum Albumin (eHSA) on Cisplatin and Etoposide Anticancer Effect in C57BL/6 Mice with Tumor and in Human NSCLC A549 Cells
    Yang, Zhen
    Zhou, Ting
    Cheng, Yuanchi
    Li, Mingming
    Tan, Xianglin
    Xu, Feng
    [J]. FRONTIERS IN PHARMACOLOGY, 2016, 7